MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
$102,773K
Free Cash flow
$95,692K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Maturity of investment securitie...
Accounts payable
Net income
Others
Negative Cash Flow Breakdown
Purchases of investment securiti...
Accounts receivable, net
Prepaid expenses and other curre...
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net income
31,500
3,637
273,568
71,779
Stock-based compensation
16,940
14,698
13,235
13,180
Amortization of premiums and accretion of discounts on investment securities
50
453
670
1,102
Amortization of intangible assets
2,723
2,722
2,722
2,723
Gain on sale of non-financial asset
-
-
0
-
Gain on strategic investment
-
-
0
-
Depreciation
434
271
202
227
Loss on sale of investment securities
-
-
0
-
Deferred income taxes
9,773
-94
-249,879
-
Accounts receivable, net
15,295
13,893
5,607
8,345
Interest and other receivables
2,660
-13,740
3,192
11,401
Inventory
-3,897
-78
4,892
-1,248
Prepaid expenses
-
-113
-
8,121
Prepaid expenses and other current assets
9,843
-
3,845
-
Other assets
-378
32
850
700
Operating lease right-of-use assets
-2,234
-2,164
-2,196
-2,212
Accounts payable
32,323
1,343
-10,844
1,650
Accrued liabilities
22,531
23,557
-68,391
27,776
Operating lease liabilities
-1,849
-2,183
-2,919
-2,179
Long-term liabilities
2,671
-6,500
5,248
-14,659
Net cash provided by operating activities
100,781
33,981
-48,731
74,288
Purchases of investment securities
93,440
15,007
157,614
204,553
Maturity of investment securities
90,000
86,500
105,750
125,589
Proceeds from sale of non-financial asset
-
-
0
-
Proceeds from sales of strategic investment
-
-
0
-
Payment of milestone and contingent payments in connection with asset acquisition
0
0
0
0
Purchases of property and equipment
5,089
5,212
4,005
388
Net cash provided by (used in) investing activities
-8,529
66,281
-55,869
-79,352
Proceeds from issuance of common stock, net of issuance costs
10,494
4,231
22,666
9,423
Net cash provided by financing activities
10,494
4,231
22,666
9,423
Effect of exchange rate changes on cash
27
25
7
0
Net increase (decrease) in cash, cash equivalents and restricted cash
102,773
104,518
-81,927
4,359
Beginning of period
290,058
185,540
267,467
328,359
End of period
392,831
290,058
185,540
267,467
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Accounts payable
$32,323K
(727.73%↑ Y/Y)
Net income
$31,500K
(-31.00%↓ Y/Y)
Accrued liabilities
$22,531K
(5.53%↑ Y/Y)
Stock-based compensation
$16,940K
(-34.14%↓ Y/Y)
Proceeds from issuance of
common stock, net of...
$10,494K
(-41.03%↓ Y/Y)
Deferred income taxes
$9,773K
something is missing
$5,074K
Inventory
-$3,897K
(-126.78%↓ Y/Y)
Amortization of intangible
assets
$2,723K
(-49.98%↓ Y/Y)
Long-term liabilities
$2,671K
(-74.54%↓ Y/Y)
Operating lease
right-of-use assets
-$2,234K
(47.55%↑ Y/Y)
Depreciation
$434K
(-1.81%↓ Y/Y)
Other assets
-$378K
(-128.94%↓ Y/Y)
Net cash provided by
operating activities
$100,781K
(19.58%↑ Y/Y)
Net cash provided by
financing activities
$10,494K
(-41.03%↓ Y/Y)
Canceled cashflow
$29,697K
Effect of exchange rate
changes on cash
$27K
(42.11%↑ Y/Y)
Net increase
(decrease) in cash, cash...
$102,773K
(257.50%↑ Y/Y)
Canceled cashflow
$8,529K
Accounts receivable, net
$15,295K
(74.48%↑ Y/Y)
Prepaid expenses and
other current assets
$9,843K
Interest and other
receivables
$2,660K
(-57.27%↓ Y/Y)
Operating lease
liabilities
-$1,849K
(-30.39%↓ Y/Y)
Amortization of premiums and
accretion of discounts on...
$50K
(-98.63%↓ Y/Y)
Maturity of investment
securities
$90,000K
(-65.67%↓ Y/Y)
Net cash provided by
(used in) investing...
-$8,529K
(94.90%↑ Y/Y)
Canceled cashflow
$90,000K
Purchases of investment
securities
$93,440K
(-71.72%↓ Y/Y)
Purchases of property and
equipment
$5,089K
(1613.47%↑ Y/Y)
Buy us a coffee
ACADIA PHARMACEUTICALS INC (ACAD)
ACADIA PHARMACEUTICALS INC (ACAD)